Abstract
Background Symptoms of allergic rhinitis can be reduced by nonpharmacological nasal sprays that create a barrier between allergens and the nasal mucosa. A new nasal spray (AM-301) containing the clay mineral bentonite was tested for its ability to reduce symptoms to grass pollen.
Methods This open label, crossover, noninferiority trial compared the efficacy and safety of AM-301 to that of hydroxypropyl methylcellulose (HPMC; Nasaleze Allergy Blocker), an established barrier method. Adults with seasonal allergic rhinitis were exposed to Dactylis glomerata pollen, in the Fraunhofer Allergen Challenge Chamber, first without protection and then protected by HPMC or AM-301 (7 days apart). Efficacy was assessed from total nasal symptom score (TNSS), nasal secretion weight, and subjective rating. The primary endpoint was the difference, between AM-301 and HPMC, in least square mean change in TNSS over a 4-hour exposure to allergen.
Results The study enrolled 36 persons, and 35 completed all study visits. The mean TNSS was 5.91 during unprotected exposure, 5.20 during protection with HPMC, and 4.82 during protection with AM-301. The difference in least square means between the two treatments was -0.39 (95% CI, -0.89 to 0.10), establishing the noninferiority of AM-301. No difference in mean weight of nasal secretions was observed between the treatments. Efficacy was rated as good or very good for AM-301 by 31% and for HPMC by 14% of subjects. 16 subjects reported adverse events with a relationship to AM-301 or HPMC; most adverse events were mild and none was serious.
Conclusions AM-301 demonstrated noninferiority towards HPMC in the primary endpoint and was perceived better in subjective secondary endpoints. Both barrier-forming products had a persisting protective effect over 4 hours and were safe.
Trial registration German Clinical Trial Register (DRKS00024356). EUDAMED (CIV-20-10-034870).
Competing Interest Statement
NG, IPH, and FF are employees of Altamira Medica and hold stock options. TM is CEO of Altamira Medica and a shareholder of Altamira Medica's parent company, Altamira Therapeutics Ltd. (formerly known as Auris Medical Ltd.). Altamira Medica has filed a provisional US patent application relating to AM-301, on which FF and TM figure as inventors. JMH, JN and PB are employees of Fraunhofer ITEM that received funding from Altamira Medica for the conduct of this study. JMH reports grants to his institution for clinical trial conduct, personal fees for lectures and consulting outside the scope of this work.
Clinical Trial
DRKS00024356
Funding Statement
The study was funded by Altamira Medica (Zug, Switzerland). Altamira Medica and Fraunhofer ITEM jointly planned and managed the study, while the study was conducted by Fraunhofer ITEM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Hannover Medical School (https://www.mhh.de/ethikkommission) Federal Institute of Drugs and Medical Devices (Bundesinstitut fuer Arzneimittel und Medizinprodukte, BfArM)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data are available from the corresponding author upon request. The medical devices used in the study are commercially available in some countries.
Abbreviations
- ACC
- allergen challenge chamber
- CI
- confidence interval
- HPMC
- hydroxypropyl methylcellulose
- ITEM
- Institute for Toxicology and Experimental Medicine
- LSmeans
- least square means
- PEF
- peak expiratory flow
- SAR
- seasonal allergic rhinitis
- SD
- standard deviation
- TNSS
- total nasal symptom score
